BioVaxys Technology (XCNQ:BIOV) Total Equity : C$-0.25 Mil (As of Jul. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Total Equity?

BioVaxys Technology's total equity for the quarter that ended in Jul. 2024 was C$-0.25 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

BioVaxys Technology Total Equity Historical Data

The historical data trend for BioVaxys Technology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Total Equity Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Total Equity

Get a 7-Day Free Trial

0.19

9.56

8.18

-0.77

-3.37

BioVaxys Technology Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Total Equity	Get a 7-Day Free Trial															-0.62	-3.37	-1.40	-1.03	-0.25

BioVaxys Technology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

BioVaxys Technology's Total Equity for the fiscal year that ended in Oct. 2023 is calculated as

Total Equity	=	Total Assets(Q: Oct. 2023 )	-	Total Liabilities(Q: Oct. 2023 )
	=	0.113	-	3.486
	=	-3.37

BioVaxys Technology's Total Equity for the quarter that ended in Jul. 2024 is calculated as

Total Equity	=	Total Assets(Q: Jul. 2024 )	-	Total Liabilities(Q: Jul. 2024 )
	=	2.408	-	2.657
	=	-0.25

BioVaxys Technology Total Equity Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (XCNQ:BIOV) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

BVAXF:USA 5LB:Germany

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.

Executives

James Passin	Director, Senior Officer
Kenneth Kovan	Senior Officer

BioVaxys Technology Headlines

No Headlines